About: Amikacin

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Amikacin Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Amikacin is a semi-synthetic aminoglycoside antibiotic derived from kanamycin A. Similar to other aminoglycosides, amikacin disrupts bacterial protein synthesis by binding to the 30S ribosome of susceptible organisms. Binding interferes with mRNA binding and tRNA acceptor sites leading to the production of non-functional or toxic peptides. Other mechanisms not fully understood may confer the bactericidal effects of amikacin. Amikacin is also nephrotoxic and ototoxic. (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B5AAD-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B5AAE-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B5AAF-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B5AB0-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B5AB1-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Edson RS, Terrell CL: The aminoglycosides. Mayo Clin Proc. 1999 May;74(5):519-28. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10319086 (en)
http://linked.open...gy/drugbank/group	approved (en)
http://linked.open...drugbank/halfLife	2-3 hours (en)
http://linked.open...ugbank/indication	For short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter (Mima-Herellea) species. Amikacin may also be used to treat Mycobacterium avium and Mycobacterium tuberculosis infections. (en)
http://linked.open...bank/manufacturer	Abbott laboratories Abbott laboratories hosp products div App pharmaceuticals llc Baxter healthcare corp anesthesia and critical care Baxter healthcare corp anesthesia and critical care Baxter healthcare corp Gd searle llc Apothecon inc div bristol myers squibb
sameAs	Amikacin Amikacin
Title	Amikacin (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB00479/identifier/chebi/2637 http://linked.opendata.cz/resource/drugbank/drug/DB00479/identifier/chemspider/34635 http://linked.opendata.cz/resource/drugbank/drug/DB00479/identifier/drugbank/DB00479 http://linked.opendata.cz/resource/drugbank/drug/DB00479/identifier/kegg-compound/C06820 http://linked.opendata.cz/resource/drugbank/drug/DB00479/identifier/kegg-drug/D02543 http://linked.opendata.cz/resource/drugbank/drug/DB00479/identifier/national-drug-code-directory/0703-9032-03 http://linked.opendata.cz/resource/drugbank/drug/DB00479/identifier/pubchem-compound/37768 http://linked.opendata.cz/resource/drugbank/drug/DB00479/identifier/pubchem-substance/46506386 http://linked.opendata.cz/resource/drugbank/drug/DB00479/identifier/pharmgkb/PA164744372 http://linked.opendata.cz/resource/drugbank/drug/DB00479/identifier/wikipedia/Amikacin
http://linked.open...mechanismOfAction	Aminoglycosides like Amikacin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Amikacin inhibits protein synthesis by binding to the 30S ribosomal subunit to prevent the formation of an initiation complex with messenger RNA. Specifically Amikacin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes. (en)
http://linked.open...drugbank/packager	Bedford Labs Ben Venue Laboratories Inc. Bristol-Myers Squibb Co. Hospira Inc. Mead Johnson and Co. Caraco pharmaceutical laboratories ltd Prepak Systems Inc. Pfizer inc
http://linked.open...outeOfElimination	Amikacin is excreted primarily by glomerular filtration. (en)
http://linked.open.../drugbank/synonym	Amikacin (en) Amicacin (en) Amikavet (en) Briclin (en) Amiglyde-v (en) Amikacina (en) Amikacine (en) Amikacinum (en) O-3-amino-3-Deoxy-alpha-D-glucopyranosyl-(1->4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->6))-N(3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine (en) 1-N-(L(-)-gamma-amino-alpha-Hydroxybutyryl)kanamycin a (en)
http://linked.open...drugbank/toxicity	Mild and reversible nephrotoxicity may be observed in 5 - 25% of patients. Amikacin accumulates in proximal renal tubular cells. Tubular cell regeneration occurs despite continued drug exposure. Toxicity usually occurs several days following initiation of therapy. May cause irreversible ototoxicity. Otoxocity appears to be correlated to cumulative lifetime exposure. Drug accumulation in the endolymph and perilymph of the inner ear causes irreversible damage to hair cells of the cochlea or summit of ampullar cristae in the vestibular complex. High frequency hearing is lost first with progression leading to loss of low frequency hearing. Further toxicity may lead to retrograde degeneration of the 8th cranial (vestibulocochlear) nerve. Vestibular toxicity may cause vertigo, nausea, vomiting, dizziness and loss of balance. (en)
http://linked.open...umeOfDistribution	* 24 L [normal adult subjects] (en)
http://linked.open.../drug/hasAHFSCode	http://linked.opendata.cz/resource/AHFS/08-12-02
http://linked.open...nk/proteinBinding	0-11% (en)
http://linked.open...ogy/drugbank/salt	(en)
http://linked.open...ynthesisReference	Alberto Mangia, Vicenzo Giobbio, Giorgio Ornato, "Novel process for the synthesis of amikacin." U.S. Patent US4902790, issued August, 1984. (en)
http://linked.open...y/mesh/hasConcept	http://linked.opendata.cz/resource/mesh/concept/M0000903
foaf:page	http://www.drugs.com/cdi/amikacin.html http://www.rxlist.com/cgi/generic3/amikacin.htm
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B5AB6-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B5ABC-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B5ABB-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B5AB8-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B5AB9-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B5ABA-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B5AB4-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B5ACC-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B5AB2-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B5AB5-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B5ACE-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B5AB3-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B5ACF-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Amikacin Amikacin Amikacin
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B5AC2-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B5AC3-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B5ABD-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B5ABE-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B5AC0-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B5ABF-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B5AC1-363D-11E5-9242-09173F13E4C5
http://linked.open...ugbank/absorption	Rapidly absorbed after intramuscular administration. Rapid absorption occurs from the peritoneum and pleura. Poor oral and topical absorption. Poorly absorbed from bladder irrigations and intrathecal administration. (en)
http://linked.open.../affectedOrganism	Enteric bacteria and other eubacteria (en)
http://linked.open...casRegistryNumber	37517-28-5 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...rugbank/clearance	* 100 mL/min (en)
http://linked.open...gbank/containedIn	Amikacin (pf) 100 mg/2 ml Amikacin 250 mg/ml vial Amikacin (pf) 500 mg/2 ml Amikacin sulfate powder
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B5AC8-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B5ACA-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B5ACB-363D-11E5-9242-09173F13E4C5
http://linked.open...ank/Melting-Point	http://linked.opendata.cz/resource/drugbank/property/271B5ACD-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B5AC7-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B5AC6-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B5AC9-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 46 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software